## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 8.7% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-9.5% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($61.53)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Arrowhead climbs to 52-week high as RNAi bets pay off**
- Source: Longevity.Technology | 20251215T170950 | Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals has experienced a dramatic turnaround in 2025, reaching a 52-week high after its RNA interference (RNAi) drug, Redemplo (plozasiran), received FDA approval for familial chylomicronemia syndrome (FCS) and Breakthrough Therapy designation for severe hypertriglyceridemia (SHTG). The company's stock has more than tripled in value over the past year, reflecting investor confidence in its validated RNAi platform, expanding pipeline into broader markets like Alzheimer's disease, and significant partnerships with major pharmaceutical companies. Despite ongoing patent litigation and clinical trial risks, Arrowhead's recent successes have solidified its position as a commercial-stage biotech player.

**2. Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approval, Plozasiran Breakthrough Status and ARO-MAPT Trial Progress**
- Source: Simply Wall Street | 20251215T040950 | Somewhat-Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals (ARWR) has seen significant clinical and regulatory progress with the FDA approval of REDEMPLO, Breakthrough Therapy status for plozasiran, and the advancement of ARO-MAPT into human trials. These developments have led to substantial share price increases, with the stock currently trading above analyst targets. Despite this positive momentum, Simply Wall St assesses the company as 22% overvalued with a fair value of $57.67, highlighting a debate over whether current growth is already priced in.

**3. WINTON GROUP Ltd Invests $660,000 in Arrowhead Pharmaceuticals, Inc. $ARWR**
- Source: MarketBeat | 20251212T190859 | Somewhat-Bullish | Relevance: 100%
- WINTON GROUP Ltd has invested $660,000 in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by purchasing 41,778 shares in Q2. Other institutional investors like Marshall Wace LLP and Pale Fire Capital SE also increased their stakes, bringing total institutional ownership to 62.61%. The stock currently holds a "Moderate Buy" consensus rating with an average price target of $58.56, and recently traded near its 12-month high.

**4. 36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc**
- Source: MarketBeat | 20251215T110950 | Somewhat-Bullish | Relevance: 100%
- Marex Group plc recently acquired 36,469 shares of Arrowhead Pharmaceuticals, Inc. ($ARWR) during the second quarter, valued at approximately $576,000, bringing institutional ownership to about 62.61%. Analysts have a "Moderate Buy" consensus with an average price target of $58.56, but company insiders have been selling shares, reducing their ownership to 4.30%. The biotechnology company currently trades near $70 with a market capitalization around $9.5 billion.

**5. Arrowhead Pharmaceuticals stock hits 52-week high at 71.62 USD**
- Source: Investing.com | 20251211T150851 | Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals (ARWR) stock has reached a new 52-week high of $71.62 USD, reflecting a significant 221.09% surge over the past year and strong investor confidence. Despite this, InvestingPro analysis suggests the stock is trading above its Fair Value and is in overbought territory. The company has also made progress in drug development, receiving FDA Breakthrough Therapy designation for plozasiran and initiating a Phase 1/2a clinical trial for ARO-MAPT, leading analysts to adjust their price targets upwards.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |
| 2025-12-01 | B of A Securiti | $62 | $42 | +48% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |
| 2025-12-01 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($2.19M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Elevated short interest (11.3%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +39%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -27% YoY, concerning. Analyst sentiment positive (9 raises, avg +39%). Insider selling cluster ($2.2M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.7B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 11.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 18.2% to 8.7% (-9.5% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (8.7% > 6.0%), caution on chasing. MRS_5 at 2.3% confirms short-term momentum alignment. Outperforming sector by 9.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.42), confirming momentum. RSI overbought at 76, risk of mean reversion. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 8.73% (CS: 97) | Strong |
| RSI_14 | 75.7 | Overbought |
| MACD Histogram | 1.42 | Bullish |
| vs SMA20 | 1.282x | Above |
| vs SMA50 | 1.556x | Above |
| vs SMA200 | 2.826x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $70.09
- **Stop Loss:** $61.53 (12.2% risk)
- **Target:** $78.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 116
- **Position Value:** $8,130.44
- **Portfolio %:** 8.13%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*